Cargando…
Delayed immune-mediated hepatitis after three cycles of pembrolizumab for the treatment of sinonasal melanoma
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that induce the anti-tumor effects of T cells by targeting co-inhibitory immune checkpoints. The development of ICIs has revolutionized the clinical practice of oncology, leading to significant improvements in outcomes; therefore, ICIs ar...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394523/ https://www.ncbi.nlm.nih.gov/pubmed/37376755 http://dx.doi.org/10.4103/jpgm.jpgm_834_22 |
_version_ | 1785083389670326272 |
---|---|
author | Kang, S Lee, HJ Lee, HJ |
author_facet | Kang, S Lee, HJ Lee, HJ |
author_sort | Kang, S |
collection | PubMed |
description | Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that induce the anti-tumor effects of T cells by targeting co-inhibitory immune checkpoints. The development of ICIs has revolutionized the clinical practice of oncology, leading to significant improvements in outcomes; therefore, ICIs are now standard care for various types of solid cancers. Immune-related adverse events, the unique toxicity profiles of ICIs, usually develop 4–12 weeks after initiation of ICI treatment; however, some cases can occur >3 months after cessation of ICI treatment. To date, there have been limited reports about delayed immune-mediated hepatitis (IMH) and histopathologic findings. Herein, we present a case of delayed IMH that occurred 3 months after the last dose of pembrolizumab, including histopathologic findings of the liver. This case suggests that ongoing surveillance for immune-related adverse events is required, even after cessation of ICI treatment. |
format | Online Article Text |
id | pubmed-10394523 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-103945232023-08-03 Delayed immune-mediated hepatitis after three cycles of pembrolizumab for the treatment of sinonasal melanoma Kang, S Lee, HJ Lee, HJ J Postgrad Med ADR Report Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that induce the anti-tumor effects of T cells by targeting co-inhibitory immune checkpoints. The development of ICIs has revolutionized the clinical practice of oncology, leading to significant improvements in outcomes; therefore, ICIs are now standard care for various types of solid cancers. Immune-related adverse events, the unique toxicity profiles of ICIs, usually develop 4–12 weeks after initiation of ICI treatment; however, some cases can occur >3 months after cessation of ICI treatment. To date, there have been limited reports about delayed immune-mediated hepatitis (IMH) and histopathologic findings. Herein, we present a case of delayed IMH that occurred 3 months after the last dose of pembrolizumab, including histopathologic findings of the liver. This case suggests that ongoing surveillance for immune-related adverse events is required, even after cessation of ICI treatment. Wolters Kluwer - Medknow 2023 2023-06-27 /pmc/articles/PMC10394523/ /pubmed/37376755 http://dx.doi.org/10.4103/jpgm.jpgm_834_22 Text en Copyright: © 2023 Journal of Postgraduate Medicine https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | ADR Report Kang, S Lee, HJ Lee, HJ Delayed immune-mediated hepatitis after three cycles of pembrolizumab for the treatment of sinonasal melanoma |
title | Delayed immune-mediated hepatitis after three cycles of pembrolizumab for the treatment of sinonasal melanoma |
title_full | Delayed immune-mediated hepatitis after three cycles of pembrolizumab for the treatment of sinonasal melanoma |
title_fullStr | Delayed immune-mediated hepatitis after three cycles of pembrolizumab for the treatment of sinonasal melanoma |
title_full_unstemmed | Delayed immune-mediated hepatitis after three cycles of pembrolizumab for the treatment of sinonasal melanoma |
title_short | Delayed immune-mediated hepatitis after three cycles of pembrolizumab for the treatment of sinonasal melanoma |
title_sort | delayed immune-mediated hepatitis after three cycles of pembrolizumab for the treatment of sinonasal melanoma |
topic | ADR Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394523/ https://www.ncbi.nlm.nih.gov/pubmed/37376755 http://dx.doi.org/10.4103/jpgm.jpgm_834_22 |
work_keys_str_mv | AT kangs delayedimmunemediatedhepatitisafterthreecyclesofpembrolizumabforthetreatmentofsinonasalmelanoma AT leehj delayedimmunemediatedhepatitisafterthreecyclesofpembrolizumabforthetreatmentofsinonasalmelanoma AT leehj delayedimmunemediatedhepatitisafterthreecyclesofpembrolizumabforthetreatmentofsinonasalmelanoma |